The Market Reports

Synopsis

The global market for Total Artificial Heart was estimated to be worth US$ 641 million in 2024 and is forecast to a readjusted size of US$ 1551 million by 2031 with a CAGR of 13.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Total Artificial Heart cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Total Artificial Heart (TAH) is a prosthetic device that is implanted into the body to replace the biological heart. A few proprietary artificial heart devices have been developed including the Syncardia TAH, AbioCor (Abiomed, Danvers, Massachusetts, USA), and CARMAT (Carmat, Velizy, France). The history of these devices and their clinical use has recently been reviewed. Among the devices listed, the Syncardia (TAH) is the only device currently in use. The CARMAT is currently undergoing feasibility studies, however, data has been limited to a handful of patients thus far. There is also no data on the use of the AbioCor or CARMAT in patients with CHD.

The Total Artificial Heart (TAH) market is experiencing rapid growth. This growth is primarily driven by several factors: first, the increasing incidence of cardiovascular diseases, particularly among the elderly population, leading to a rise in end-stage heart failure patients. Second, the shortage of heart transplant donors makes TAH an effective alternative, especially as a bridging therapy. Third, advancements in TAH technology, including miniaturization and improved durability and reliability, have made it a viable clinical option. Additionally, governmental and healthcare institutions' emphasis on cardiovascular disease treatment and insurance coverage for high-cost therapies have supported the development of the TAH market.

Despite the promising outlook, the TAH market faces several challenges and risks. First, the high cost of TAH limits its accessibility, particularly in developing countries. Second, long-term use of TAH may be associated with complications such as infections, thrombosis, and mechanical failures, impacting patient quality of life and treatment outcomes. Third, the complexity of TAH implantation surgery requires specialized medical teams, and postoperative management demands significant resources. Furthermore, the lifestyle changes required for long-term TAH use, including mobility restrictions and psychological adaptation, need to be carefully considered in patient care.

As TAH technology matures and clinical applications expand, downstream demand is becoming more diversified. Hospitals and medical centers, particularly heart transplant centers and intensive care units, are increasing their demand for TAH. Insurance companies are gradually expanding coverage for TAH, improving its accessibility for patients. Additionally, patient preferences for high-quality life have made comfort and convenience important considerations in TAH design and development. With the global aging population and the high incidence of cardiovascular diseases, the demand for TAH is expected to continue growing, establishing it as a crucial component in the treatment of heart failure in the coming decades.

This report aims to provide a comprehensive presentation of the global market for Total Artificial Heart, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Total Artificial Heart by region & country, by Type, and by Application.

The Total Artificial Heart market size, estimations, and forecasts are provided in terms of sales volume (Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Total Artificial Heart.

Market Segmentation

By Company

• SynCardia Systems
• Carmat
• Abbott Laboratories
• Abiomed
• Berlin Heart

Segment by Type

• SynCardia
• Others

Segment by Application

• Dilated Cardiomyopathy
• Ischemic Cardiomyopathy
• Others

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.